Skip to main content

Tekmira Q2 Losses Up on Lower Revenues, Higher Expenses


Tekmira Pharmaceuticals this week reported a jump in its second-quarter net loss as revenues shrank and expenses increased.

For the three-month period ended June 30, Tekmira's net loss rose to $4.2 million from $2.3 million in the same period a year earlier.

Contributing to the higher loss was a decline in revenues to $2.3 million from $3.8 million, which the company attributed to fluctuations in demand for its manufacturing services and the timing of milestone payments from collaborators.

Research, development, and collaboration spending increased in the quarter to $4.8 million from $4.4 million, reflecting the costs associated with preparations for clinical testing of two of Tekmira's drug candidates, the hypercholesterolemia treatment TKM-ApoB (formerly ApoB SNALP) and TKM-PLK1 (formerly PLK1 SNALP).

General and administrative costs were flat at $1.1 million.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.